|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Sir Andrew Witty
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
67,867
(Deferred)
|
|
||
|
|
£0.0000
|
22,621
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
90,448
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Sir Andrew Witty
|
|||
|
b)
|
Position/status
|
Chief Executive Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3353
|
31,898
(Deferred)
|
|
||
|
|
£16.3353
|
10,633
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
42,531
£16.3353
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
CEO Designate
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
14,860
(Deferred)
|
|
||
|
|
£0.0000
|
4,954
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
19,814
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2017-02-21
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Ms E Walmsley
|
|||
|
b)
|
Position/status
|
CEO Designate
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 21 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3500
|
6,986
(Deferred)
|
|
||
|
|
£16.3500
|
2,330
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
9,316
£16.3500
|
||||
|
e)
|
Date
of the transaction
|
2017-02-21
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Mr D S Redfern
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
12,115
(Deferred)
|
|
||
|
|
£0.0000
|
4,039
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
16,154
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Mr D S Redfern
|
|||
|
b)
|
Position/status
|
Chief Strategy Officer
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20
February 2017 under the
Company’s Deferred Annual Bonus Plan – Deferred Bonus
and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3425
|
5,809
(Deferred)
|
|
||
|
|
£16.3450
|
1,937
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
7,746
£16.3431
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Ms C Thomas
|
|||
|
b)
|
Position/status
|
SVP, Human Resources
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
7,517
(Deferred)
|
|
||
|
|
£0.0000
|
2,506
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
10,023
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Ms C Thomas
|
|||
|
b)
|
Position/status
|
SVP, Human Resources
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20 February 2017 under
the Company’s Deferred Annual Bonus Plan – Deferred
Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3700
|
3,604
(Deferred)
|
|
||
|
|
£16.3550
|
1,202
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
4,806
£16.3662
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Mr P C Thomson
|
|||
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The exercise of nil-cost options over Ordinary Shares granted on 12
February 2014 under the Company’s 2009 Deferred Annual Bonus
Plan – Deferred Bonus and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£0.0000
|
4,528
(Deferred)
|
|
||
|
|
£0.0000
|
1,509
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
6,037
£0.0000
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
n/a
|
|||
|
1.
|
Details of PDMR/person closely associated with them
(‘PCA’)
|
||||
|
a)
|
Name
|
Mr P C Thomson
|
|||
|
b)
|
Position/status
|
SVP, Communications & Government Affairs
|
|||
|
c)
|
Initial
notification/
amendment
|
Initial Notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
|
b)
|
Nature
of the transaction
|
The sale of Ordinary Shares to meet tax liabilities on nil-cost
options over Ordinary Shares exercised on 20
February 2017 under the
Company’s Deferred Annual Bonus Plan – Deferred Bonus
and Matching Awards.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£16.3450
|
2,171
(Deferred)
|
|
||
|
|
£16.3500
|
724
(Matching)
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
|
|||
|
Aggregated
volume Price
|
2,895
£16.3462
|
||||
|
e)
|
Date
of the transaction
|
2017-02-20
|
|||
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|||